Lusutrombopag

Drug Profile

Lusutrombopag

Alternative Names: MULPLETA; S-888711

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Shionogi
  • Class Small molecules; Thiazoles
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thrombocytopenia
  • Discontinued Immune thrombocytopenic purpura

Most Recent Events

  • 19 Apr 2017 Shionogi completes a phase III trial in USA, Austria, Czech Republic, Germany, Italy, United Kingdom, Belgium, Canada, Hungary, Spain, Australia, France, Israel, South Korea, Poland, Romania, Russia, Taiwan, Thailand, Turkey, Ukraine (NCT02389621)
  • 08 Jun 2016 Shionogi initiates a phase I/II trial in Thrombocytopenia in Japan (JapicCTI-163289)
  • 01 Dec 2015 Launched for Thrombocytopenia in Japan (PO) - First global launch
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top